argenx (ARGX) Research Coverage Started at Evercore ISI
ARGX has been the subject of several other reports. Stifel Nicolaus reissued a buy rating and issued a $139.00 price objective on shares of argenx in a research report on Wednesday, October 10th. Nomura started coverage on argenx in a research report on Friday, June 29th. They issued a buy rating and a $161.00 price objective for the company. JMP Securities increased their price objective on argenx to $150.00 and gave the company an outperform rating in a research report on Monday, September 17th. SunTrust Banks increased their price objective on argenx to $132.00 and gave the company an in-line rating in a research report on Tuesday, September 18th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $154.00 target price on shares of argenx in a research note on Monday, September 17th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $130.50.
ARGX opened at $78.26 on Monday. argenx has a 1-year low of $22.21 and a 1-year high of $103.00. The company has a market capitalization of $2.44 billion, a PE ratio of -55.90 and a beta of 2.43.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Article: Technical Analysis of Stocks and What It Means
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.